Our main product, Glycosorb®-ABO reduce anti-A/B antibodies in human plasma through A/B antigen specific binding. Glycosorb®-ABO has been used clinically since 2001. To date, more than 170 transplant centres on four continents have treated more than 3,000 adult and paediatric patients. The outcomes of ABO-incompatible live donor kidney transplants performed with Glycosorb®-ABO have been reported to be equivalent to those of ABO-incompatible live donor kidney transplants even at 10-year follow-up. Glycosorb®-ABO is increasingly used in ABO-incompatible deceased and live donor liver transplants, as well as in ABO-incompatible stem cell transplants and paediatric heart- and lung transplants, with good reported outcomes.